未知生产厂商
Talquetamab is a bispecific antibody used to treat adults with relapsed or refractory multiple myeloma.
Talquetamab is a bispecific antibody used to treat adults with relapsed or refractory multiple myeloma.
G protein-coupled receptor class C group 5 member D (GPRC5D) is an orphan G protein-coupled receptor predominantly expressed in cells with a plasma-cell phenotype, including the malignant plasma cells in multiple myeloma (MM). This transmembrane receptor protein is often aberrantly expressed in MM cells. In contrast, in normal tissues, it is primarily expressed in epithelial cells that produce hard keratin in the skin and tongue. Talquetamab is a bispecific T-cell-engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells and GPRC5D expressed on the surface of MM cells. It works to recruit CD3-expressing T cells to GPRC5D-expressing MM cells to induce T-cell–mediated cytotoxicity, prevent tumour growth, and promote tumour regression. When activated, T cells cause the release of proinflammatory cytokines, promoting the lysis of MM cells.
In the US, talquetamab is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. In Europe, talquetamab is indicated in patients who received at least three prior therapies and have demonstrated disease progression on the last therapy. These indications are contingent, as talquetamab is only approved under accelerated approval in the US and conditional marketing authorization in Europe. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
共 2 项相关疾病
